Women's Health & Gynecology Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls

This Phase 3 trial is testing whether giving fewer doses of two HPV vaccines can still protect girls aged 9 to 14 in Tanzania from HPV infection and cervical cancer. If this approach works, it could lower the cost of vaccination and make it easier for more girls in Africa to receive protection against these diseases. The study is following 930 girls for up to 9 years to see how long the immune response lasts.

Sentinel Node Biopsy in Endometrial Cancer

This Phase 3 study compares sentinel node biopsy with no lymph node removal during surgery for early-stage endometrial cancer. The goal is to find out if sentinel node biopsy can reduce surgery complications, like swelling of the limbs, while still effectively controlling the cancer. The trial is enrolling 760 women worldwide, including younger women who want to keep their ovaries.

A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer

This Phase 2 trial looked at the immunotherapy drug pembrolizumab in patients with advanced clear cell gynecological cancer, a rare and hard-to-treat type. The study has finished and results are available, offering new information on treatment options that might improve outcomes for these patients. It involved multiple centers across the United Kingdom.

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

This Phase 2 trial is testing whether giving the drug niraparib after 3 cycles of chemotherapy is as effective as after 6 cycles for advanced ovarian and related cancers with specific genetic features. Shortening chemotherapy could reduce side effects while still controlling the cancer. Patients with no remaining tumor after surgery are being recruited across Europe for this study.

Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer

This Phase 2 trial is investigating a new drug called mazdutide combined with a hormonal intrauterine device for overweight or obese patients with early atypical endometrial hyperplasia or endometrial cancer. This approach aims to preserve fertility and avoid more invasive treatments. The study plans to enroll 128 participants in China and will evaluate results after 24 weeks.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.